{"id":"https://openalex.org/W4362555871","doi":"https://doi.org/10.1158/2159-8290.22541231.v1","title":"Supplementary Table from Converting Tumoral PD-L1 into a 4-1BB Agonist for Safer and More Effective Cancer Immunotherapy","display_name":"Supplementary Table from Converting Tumoral PD-L1 into a 4-1BB Agonist for Safer and More Effective Cancer Immunotherapy","publication_year":2023,"publication_date":"2023-04-04","ids":{"openalex":"https://openalex.org/W4362555871","doi":"https://doi.org/10.1158/2159-8290.22541231.v1"},"language":"en","primary_location":{"id":"doi:10.1158/2159-8290.22541231.v1","doi":"https://doi.org/10.1158/2159-8290.22541231.v1","is_oa":true,"landing_page_url":"https://doi.org/10.1158/2159-8290.22541231.v1","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"volume":null,"type":"supplementary-materials","indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://doi.org/10.1158/2159-8290.22541231.v1","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5002360335","display_name":"Zihai Li","orcid":"https://orcid.org/0000-0003-4603-927X","observed_orcids":["https://orcid.org/0000-0003-4603-927X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Zihai Li","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-4603-927X","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5032091697","display_name":"Joseph H. Azar","orcid":"https://orcid.org/0000-0001-9518-2908","observed_orcids":["https://orcid.org/0000-0001-9518-2908"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Joseph H. Azar","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5046739998","display_name":"Mark P. Rubinstein","orcid":"https://orcid.org/0000-0003-4748-0286","observed_orcids":["https://orcid.org/0000-0003-4748-0286","https://orcid.org/0000-0002-9942-7519"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Mark P. Rubinstein","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9854000210762024,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9854000210762024,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.00930000003427267,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10031","display_name":"T-cell and B-cell Immunology","score":0.0010000000474974513,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/pd-l1","display_name":"PD-L1","score":0.9739999771118164},{"id":"https://openalex.org/keywords/4-1bb","display_name":"4-1BB","score":0.8840000033378601},{"id":"https://openalex.org/keywords/cancer-immunotherapy","display_name":"cancer immunotherapy","score":0.7039999961853027},{"id":"https://openalex.org/keywords/agonists","display_name":"agonists","score":0.4050000011920929},{"id":"https://openalex.org/keywords/immune-checkpoint-blockade","display_name":"immune checkpoint blockade","score":0.574999988079071},{"id":"https://openalex.org/keywords/tumor-immunology","display_name":"tumor immunology","score":0.34599998593330383}],"concepts":[{"id":"https://openalex.org/C2776654903","wikidata":"https://www.wikidata.org/wiki/Q2601463","display_name":"SAFER","level":2,"score":0.7623040080070496},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.6707445383071899},{"id":"https://openalex.org/C2778938600","wikidata":"https://www.wikidata.org/wiki/Q389934","display_name":"Agonist","level":3,"score":0.6397808790206909},{"id":"https://openalex.org/C45235069","wikidata":"https://www.wikidata.org/wiki/Q278425","display_name":"Table (database)","level":2,"score":0.6066185832023621},{"id":"https://openalex.org/C2780674031","wikidata":"https://www.wikidata.org/wiki/Q2012719","display_name":"Cancer immunotherapy","level":4,"score":0.5513812303543091},{"id":"https://openalex.org/C2781053074","wikidata":"https://www.wikidata.org/wiki/Q21100639","display_name":"PD-L1","level":4,"score":0.4721510410308838},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.4648436903953552},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.45418205857276917},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.41027718782424927},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.39816007018089294},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.33948689699172974},{"id":"https://openalex.org/C41008148","wikidata":"https://www.wikidata.org/wiki/Q21198","display_name":"Computer science","level":0,"score":0.25150731205940247},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.11534500122070312},{"id":"https://openalex.org/C124101348","wikidata":"https://www.wikidata.org/wiki/Q172491","display_name":"Data mining","level":1,"score":0.11404150724411011},{"id":"https://openalex.org/C38652104","wikidata":"https://www.wikidata.org/wiki/Q3510521","display_name":"Computer security","level":1,"score":0.0}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.1158/2159-8290.22541231.v1","doi":"https://doi.org/10.1158/2159-8290.22541231.v1","is_oa":true,"landing_page_url":"https://doi.org/10.1158/2159-8290.22541231.v1","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},{"id":"pmh:oai:figshare.com:article/22541231","doi":null,"is_oa":true,"landing_page_url":"https://figshare.com/articles/journal_contribution/Supplementary_Table_from_Converting_Tumoral_PD-L1_into_a_4-1BB_Agonist_for_Safer_and_More_Effective_Cancer_Immunotherapy/22541231","pdf_url":null,"source":{"id":"https://openalex.org/S4377196282","display_name":"Figshare","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210132348","host_organization_name":"Figshare (United Kingdom)","host_organization_lineage":["https://openalex.org/I4210132348"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"Text"}],"best_oa_location":{"id":"doi:10.1158/2159-8290.22541231.v1","doi":"https://doi.org/10.1158/2159-8290.22541231.v1","is_oa":true,"landing_page_url":"https://doi.org/10.1158/2159-8290.22541231.v1","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9537000060081482,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4362555834","https://openalex.org/W4225266732","https://openalex.org/W4282945728","https://openalex.org/W3212904207","https://openalex.org/W3181727958","https://openalex.org/W4409626799","https://openalex.org/W4392722685","https://openalex.org/W2767731416","https://openalex.org/W2321746654","https://openalex.org/W3178258886"],"abstract_inverted_index":{"Supplementary":[0],"Table":[1],"from":[2],"Converting":[3],"Tumoral":[4],"PD-L1":[5],"into":[6],"a":[7],"4-1BB":[8],"Agonist":[9],"for":[10],"Safer":[11],"and":[12],"More":[13],"Effective":[14],"Cancer":[15],"Immunotherapy":[16]},"counts_by_year":[],"updated_date":"2026-10-09T09:14:12.587421","created_date":"2023-04-06T00:00:00"}